Short but sweet message from me. I've been reflecting over the last few days since DKD readouts and am amazed at how brutally DXB has been sold off. The results were pretty good when you consider patients with high albuminuria content. Multiple patients received greater than 25% (clinically significant) reduction. Also FSGS results were outstanding. The below slide is worth more than our $50m mcap alone. Plenty of disappointed shareholders but the company is in great stead
Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-274
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $223.0M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 41.5¢ | 40.0¢ | $337.0K | 827.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7500 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 76500 | 5 |
View Market Depth
| Last trade - 10.13am 10/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |